R. Sacco

Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma

M. C. Plaz Torres, G. Cabibbo, C. Campani, 2024, Liver international : official journal of the International Association for the Study of the Liver.

Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care.

G. Rapaccini, C. Campani, A. Masotto, 2024, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib

T. Pressiani, F. Foschi, V. Sansone, 2024, Gastroenterology Insights.

Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

T. Pressiani, F. Ponziani, G. Cabibbo, 2024, Internal and emergency medicine.

Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

T. Pressiani, F. Foschi, A. Granito, 2024, Current oncology.

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

P. Malfertheiner, A. Gasbarrini, C. Bartolozzi, 2022, Cancer Imaging.